Adam V. Patterson

23 Symonds St
Auckland, AUK 1010, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor Activity.

Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor Activity.

Journal: Journal of medicinal chemistry

Published: May 28, 2026

Structure-Based Design of 4-(1-Methyl-1H-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors.

Structure-Based Design of 4-(1-Methyl-1H-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors.

Journal: Journal of medicinal chemistry

Published: February 06, 2026

Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapy.

Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapy.

Journal: Acta pharmacologica Sinica

Published: January 10, 2026

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Journal: Journal of medicinal chemistry

Published: January 06, 2026

Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance.

Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance.

Journal: Journal of medicinal chemistry

Published: September 08, 2025

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.

Journal: Bioorganic chemistry

Published: February 27, 2025

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: September 08, 2024

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623.

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623.

Journal: International journal of molecular sciences

Published: May 25, 2024

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

Journal: Journal of medicinal chemistry

Published: February 13, 2024

Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy?

Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy?

Journal: Critical reviews in microbiology

Published: February 12, 2024

Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery.

Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery.

Journal: Molecular diagnosis & therapy

Published: January 07, 2024

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.

Journal: Journal of medicinal chemistry

Published: September 05, 2023

Showing 1-12 of 69

Last Updated: 09/26/2026